跳至主要内容
临床试验/CTRI/2017/09/009695
CTRI/2017/09/009695已完成4 期

Study of anti-atherogenic effects of rosuvastatin in patients with type 2 diabetes mellitus

Sri Venkateswara Institute of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Newly diagnosed male patients with T2DM aged between 40-70 years as per the revised ADA criteria (37):i.e
  • i) Fasting plasma glucose =126mg/dL (7.0mmol/L)
  • ii) 2 hour plasma glucose =200mg/dL (11.1mmol/L)
  • iii) Glycosylated hemoglobin (HbA1c) >6.5% (48 mmol/mol)
  • Patients with T2DM on oral antidiabetic treatment and with LDL levels > 75 mg/dl will be included.

排除标准

  • Female patients with type 2 Diabetes mellitus
  • Patients with other forms of Diabetes (T1DM, Gestational diabetes mellitus)
  • Those on insulin therapy
  • Thyroid disorders not on treatment
  • Those on pioglitazone
  • Liver and kidney diseases
  • Other inflammatory diseases
  • Acute illness
  • Current smoking
  • On cholesterol lowering drugs
  • Individuals who are not willing to participate

研究者

相似试验

Effect of the drug Rosuvastatin in lowering the risk... | 临床试验